SE9602931L - Ny medicinsk användning - Google Patents

Ny medicinsk användning

Info

Publication number
SE9602931L
SE9602931L SE9602931A SE9602931A SE9602931L SE 9602931 L SE9602931 L SE 9602931L SE 9602931 A SE9602931 A SE 9602931A SE 9602931 A SE9602931 A SE 9602931A SE 9602931 L SE9602931 L SE 9602931L
Authority
SE
Sweden
Prior art keywords
medical use
new medical
treatment
heparin
chitosan
Prior art date
Application number
SE9602931A
Other languages
English (en)
Other versions
SE507028C2 (sv
SE9602931D0 (sv
Inventor
Olle Larm
Marcus Back
Tomas Bergstroem
Original Assignee
Medicarb Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb Ab filed Critical Medicarb Ab
Priority to SE9602931A priority Critical patent/SE507028C2/sv
Publication of SE9602931D0 publication Critical patent/SE9602931D0/sv
Priority to NZ333925A priority patent/NZ333925A/xx
Priority to AT97934838T priority patent/ATE215829T1/de
Priority to EP97934838A priority patent/EP0930885B1/en
Priority to DE69711897T priority patent/DE69711897T2/de
Priority to CN97197038A priority patent/CN1227493A/zh
Priority to CA002261742A priority patent/CA2261742A1/en
Priority to JP10507859A priority patent/JP2000515543A/ja
Priority to ES97934838T priority patent/ES2174273T3/es
Priority to PCT/SE1997/001320 priority patent/WO1998005341A1/en
Priority to AU37911/97A priority patent/AU705189B2/en
Priority to DK97934838T priority patent/DK0930885T3/da
Priority to US09/230,021 priority patent/US6207653B1/en
Publication of SE9602931L publication Critical patent/SE9602931L/sv
Publication of SE507028C2 publication Critical patent/SE507028C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SE9602931A 1996-08-06 1996-08-06 Ny medicinsk användning SE507028C2 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning
US09/230,021 US6207653B1 (en) 1996-08-06 1997-08-01 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
CA002261742A CA2261742A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
ES97934838T ES2174273T3 (es) 1996-08-06 1997-08-01 Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes.
EP97934838A EP0930885B1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
DE69711897T DE69711897T2 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
CN97197038A CN1227493A (zh) 1996-08-06 1997-08-01 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染
NZ333925A NZ333925A (en) 1996-08-06 1997-08-01 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
JP10507859A JP2000515543A (ja) 1996-08-06 1997-08-01 ヘルペスウイルスにより起こる感染を予防または治療するためのキトサンと組み合わされたヘパリンまたはヘパラン硫酸の使用
AT97934838T ATE215829T1 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
PCT/SE1997/001320 WO1998005341A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
AU37911/97A AU705189B2 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
DK97934838T DK0930885T3 (da) 1996-08-06 1997-08-01 Anvendelsen af heparin eller heparansulfat kombineret med chitosan til forebyggelsen eller behandlingen af infektioner af herpesvirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning

Publications (3)

Publication Number Publication Date
SE9602931D0 SE9602931D0 (sv) 1996-08-06
SE9602931L true SE9602931L (sv) 1998-02-07
SE507028C2 SE507028C2 (sv) 1998-03-16

Family

ID=20403528

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning

Country Status (13)

Country Link
US (1) US6207653B1 (sv)
EP (1) EP0930885B1 (sv)
JP (1) JP2000515543A (sv)
CN (1) CN1227493A (sv)
AT (1) ATE215829T1 (sv)
AU (1) AU705189B2 (sv)
CA (1) CA2261742A1 (sv)
DE (1) DE69711897T2 (sv)
DK (1) DK0930885T3 (sv)
ES (1) ES2174273T3 (sv)
NZ (1) NZ333925A (sv)
SE (1) SE507028C2 (sv)
WO (1) WO1998005341A1 (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508760C2 (sv) 1997-04-29 1998-11-02 Medicarb Ab Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
AU7070700A (en) * 1999-08-25 2001-03-19 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
CA2630823C (en) 2005-12-13 2015-02-10 Exthera Ab Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
US8906883B2 (en) * 2009-06-10 2014-12-09 Exthera Ab Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
CA2782311C (en) 2009-12-01 2017-06-27 Robert S. Ward Method for removing cytokines from blood with surface immobilized polysaccharides
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
KR101800773B1 (ko) * 2010-04-07 2017-11-23 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 보존안정성이 우수한 ｓ-아데노실-ｌ-메티오닌 함유 건조 효모 조성물 및 그 제조 방법
WO2011142484A1 (ja) * 2010-05-14 2011-11-17 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
WO2013188073A1 (en) 2012-06-13 2013-12-19 Exthera Medical, Llc Use of heparin and carbohydrates to treat cancer
JP6648009B2 (ja) 2013-06-24 2020-02-14 エクステラ・メディカル・コーポレーション マンノース被覆基材を含有する血液濾過システム
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
DE15782250T1 (de) 2014-04-24 2017-08-10 Exthera Medical Corporation Verfahren zur Entfernung von Bakterien aus Blut unter Verwendung einer hohen Durchflussrate
CN106714669B (zh) 2014-09-22 2021-05-14 艾克塞拉医疗公司 可穿戴的血液灌流装置
US10786615B2 (en) 2016-03-02 2020-09-29 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2022079142A1 (en) * 2020-10-14 2022-04-21 Medoderm Gmbh Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (en) 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

Also Published As

Publication number Publication date
AU3791197A (en) 1998-02-25
DK0930885T3 (da) 2002-05-06
ES2174273T3 (es) 2002-11-01
SE507028C2 (sv) 1998-03-16
ATE215829T1 (de) 2002-04-15
EP0930885B1 (en) 2002-04-10
NZ333925A (en) 2000-07-28
US6207653B1 (en) 2001-03-27
EP0930885A1 (en) 1999-07-28
JP2000515543A (ja) 2000-11-21
DE69711897T2 (de) 2002-08-22
AU705189B2 (en) 1999-05-20
WO1998005341A1 (en) 1998-02-12
CA2261742A1 (en) 1998-02-12
SE9602931D0 (sv) 1996-08-06
DE69711897D1 (de) 2002-05-16
CN1227493A (zh) 1999-09-01

Similar Documents

Publication Publication Date Title
SE9602931L (sv) Ny medicinsk användning
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
EE9800382A (et) Lihtherpese viiruse ja teiste nakkushaiguste antimikroobne ravimenetlus
ATE500808T1 (de) Onkolytische virustherapie
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
IL143512A (en) Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
DE68904264T2 (de) Fragmente und fraktionen von heparin mit wirkung gegen hiv.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
SE9303612D0 (sv) New use
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO2001066100A3 (en) Pharmaceutical composition
AU2396900A (en) Treatment and prevention of hiv and other viral infections
ES2128322T3 (es) Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos.
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
LTIP1943A (en) Arylating agents, used in the treatment of cancerand disease caused by viral infection
RU92016457A (ru) Антикоагулирующий препарат
MX9201711A (es) Metodo para retardar y reducir la aparicion del virus resistente a analogos de nucleosidos, en un paciente que tiene una infeccion por vih.
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
WO2001013910A3 (en) Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
DZ2898A1 (fr) Prévention antimicrobienne et traitement contre levirus du syndrome immunodéficitaire acquis et aut res maladies contagieuses.
RU95115387A (ru) Способ лечения хирургической инфекции
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus

Legal Events

Date Code Title Description
NUG Patent has lapsed